Trials / Completed
CompletedNCT06104319
Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH
A Phase 2a, Single Dose, Open-label, Dose Exploration Study to Assess the PK-PD Activity, Safety, and Tolerability of GSK4532990 in Adult. Participants With NASH or Suspected NASH
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated. The total study duration for each participant will be approximately 24-36 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK4532990 | GSK4532990 will be administered |
Timeline
- Start date
- 2024-01-22
- Primary completion
- 2025-09-23
- Completion
- 2025-09-23
- First posted
- 2023-10-27
- Last updated
- 2025-10-14
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06104319. Inclusion in this directory is not an endorsement.